08-11-2011: Ablynx announced that it has regained worldwide rights from Pfizer Inc. to develop and commercialise Nanobodies targeting TNF-alpha. These rights include the product ATN-103, for which positive proof-of-concept data from a Phase II trial in rheumatoid arthritis (RA) were announced in May of this year; and the product PF-05230905, which is in Phase I trials. Ablynx will undertake a detailed review of the programmes before deciding how to proceed.
The 2006 agreement which Ablynx entered into with Wyeth (acquired by Pfizer in 2009) has been terminated and all licensed rights under Ablynx intellectual property relating to the anti-TNF-alpha programmes are being returned to Ablynx. In addition, Ablynx will also obtain certain Pfizer intellectual property and know-how relating to the anti-TNF-alpha programmes and will have access to Pfizer's existing clinical trial supplies of ATN-103 and PF-05230905, assay methods and manufacturing processes for use in future development activities. In return for these rights and assets, after potential regulatory approval of the first anti-TNF-alpha Nanobody, Ablynx will start to share with Pfizer, milestone payments it receives from any third party licensee of the anti-TNF-alpha Nanobody programmes, up to a capped amount of $50 million, as well as paying a royalty on sales of such products.
Dr Jose-Carlos Gutierrez-Ramos, Head of BioTherapeutics Research and Development, Pfizer, added: "We have enjoyed a very productive collaboration with Ablynx. Our decision to return this programme to Ablynx was made as part of Pfizer's portfolio review process. We wish Ablynx success with ATN-103 and PF-05230905."
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the coll ... more
Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.Dr Perlmutter was Executive Vice President, Research an ... more
Ablynx announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.Th ... more
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currentl ... more
The SFJ Pharmaceuticals Group (SFJ), announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer’s investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804). The tria ... more
Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive rig ... more
Ablynx announced that it has regained worldwide rights from Pfizer Inc. to develop and commercialise Nanobodies targeting TNF-alpha. These rights include the product ATN-103, for which positive proof-of-concept data from a Phase II trial in rheumatoid arthritis (RA) were announced in May of ... more